Update - AnteoTech signs manufacturing contract with Operon
Filed with ASX · · 3 pages · English
❖ AnteoTech signs EuGeni COVID-19 ART contract manufacturing agreement with Operon. ❖ AnteoTech to enhance Quality Management System (QMS) and seek MDSAP certification to facilitate single audit process for major market regulatory authorities. ❖ Saliva use case on track for CE Mark update in June 2021. AnteoTech Ltd (ASX: ADO) (“AnteoTech” or “the Company”) is pleased to announce that it has final
Earlier from AnteoTech
- Share Purchase Plan Offer Booklet
- Proposed issue of Securities - ADO
- Energy Collaborator Program Creates Commercial Pathway
- Test Platform and COVID-19 Test receive CE Mark approval
- AnteoTech Joins $130M Future Battery Industries CRC
Later from AnteoTech
- AnteoTech raises $8.0m in strongly supported SPP
- EuGeni Test Strip Manufacturing Strategy
- AnteoTech Signs SE Asian Distribution Agreement for EuGeni
- AnteoTech Signs Australian Distribution Agreement for EuGeni
- AnteoTech Signs UK Distribution Agreement for EuGeni
Follow AnteoTech into a list and get an email when it puts out news.
Follow AnteoTech